This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Medline (MDLN), Danaher (DHR)

Tipranks - Tipranks - Fri Jun 12, 7:56AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medline (MDLN) and Danaher (DHR) with bullish sentiments.

Introducing TipRanks MCP for Agents

Medline (MDLN)

BTIG analyst David Larsen reiterated a Buy rating on Medline on June 9 and set a price target of $55.00. The company’s shares closed last Wednesday at $36.54.

According to TipRanks.com, Larsen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.2% and a 34.6% success rate. Larsen covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Definitive Healthcare Corp, and Lifestance Health Group. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Medline with a $52.16 average price target, representing a 44.6% upside. In a report issued on June 3, TipRanks – PerPlexity also upgraded the stock to Buy with a $40.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Danaher (DHR)

Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Danaher yesterday and set a price target of $270.00. The company’s shares closed last Wednesday at $183.63.

According to TipRanks.com, Ryskin is a 3-star analyst with an average return of 1.9% and a 50.4% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Danaher with a $228.80 average price target, representing a 22.4% upside. In a report issued on May 27, Citi also initiated coverage with a Buy rating on the stock with a $230.00 price target.

Read More on MDLN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).